A New Stage 4 Clinical Trial for Colorectal Cancer
As a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Fox Chase Cancer Center offers our patients the most advanced treatment options through clinical trials, many of which are not readily available elsewhere. Our nationally ranked doctors specialize in the development of these studies — specifically phase 1 and 2 trials.
In this issue we highlight a pilot clinical trial for stage 4 colorectal cancer that will be led by Efrat Dotan, a medical oncologist at Fox Chase who specializes in gastrointestinal malignancies.
The purpose of the clinical trial is to find out the safest dose of drug eluting irinotecan beads (DEBIRI) for treating patients who have colorectal cancer with liver metastases. This trial will study whether liver metastases respond to treatment with DEBIRI. Patients will receive DEBIRI in the interventional radiology department and stay in the hospital for observation following treatment. Researchers will be studying DEBIRI in future clinical trials to learn more about its side effects and use in stage 4 colorectal cancer with liver metastases.
About 30 patients over the age of 18 years who have stage 4 colorectal cancer with liver metastases will participate in this study. Patients must also have had previous treatment for their cancer with fluoropyrimidine, oxaliplatin and irinotecan.
Learn more about clinical trials offered at Fox Chase.